NYSE · Healthcare · Medical Devices
Boston Scientific Corporation (BSX)
As of Sep 25, 4:00 PM ET, Boston Scientific (BSX) last traded at $43.92, down 1.70% on the day. Its TickerHum research score is 53/100 (average). It reported revenue of $21B for the twelve months ending 2026-06-30, up 13.5% year over year, with a 19.8% operating margin.
Ratings
- Valuation: 83/100 — Strongest input: price / sales (ttm) 3.0x. Weakest: free-cash-flow yield 5.7 %.
- Growth: 80/100 — Strongest input: diluted eps growth (ttm, yoy) +47.0 %. Weakest: revenue growth (ttm, yoy) +13.5 %.
- Profitability: 73/100 — Strongest input: gross margin 69.9 %. Weakest: return on equity 14.7 %.
- Financial health: 37/100 — Strongest input: long-term debt / equity 0.44. Weakest: cash / long-term debt 0.05.
- Momentum: 11/100 — Strongest input: 3-month return -0.7 %. Weakest: price vs 200-day average -30.2 %.
- Attention: 55/100 — Strongest input: headlines in the last 7 days 16. Weakest: volume vs 3-month average 0.7x.
- Risk: 32/100 — Strongest input: annualised volatility (1y) 39.7 %. Weakest: max drawdown (1y) -59.4 %.
- Data confidence: 92/100 — Strongest input: inputs available 100 %. Weakest: quote age (hours) 45 h.
Reported fundamentals
| Metric | Value | Period |
|---|---|---|
| Revenue | $21B | TTM ending 2026-06-30 · 10-Q |
| Revenue growth | 13.5% | TTM ending 2026-06-30 · 10-Q |
| Net income | $3.67B | TTM ending 2026-06-30 · 10-Q |
| Diluted EPS | $2.47 | TTM ending 2026-06-30 · 10-Q |
| Gross margin | 69.9% | TTM ending 2026-06-30 · 10-Q |
| Operating margin | 19.8% | TTM ending 2026-06-30 · 10-Q |
| Net margin | 17.5% | TTM ending 2026-06-30 · 10-Q |
| Free cash flow | $3.63B | TTM ending 2026-06-30 · 10-Q |
| Cash | $539M | as of 2026-06-30 · 10-Q |
| Long-term debt | $10.92B | as of 2026-06-30 · 10-Q |
| Debt / equity | 0.44 | as of 2026-06-30 · 10-Q |
Source: SEC EDGAR XBRL company facts (CIK 0000885725).
Prices: Yahoo Finance (public) — Free public Yahoo Finance data. Prices may be delayed and are for information only.